Genelux Corporation
Genelux Corporation (GNLX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GNLX · as of Jun 8, 2026
Key Statistics
Explore Genelux Corporation Data
gnlx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 66.7%
The GNLX analyst consensus is Buy, based on ratings from 3 Wall Street analysts over the past 3 months. The average 12-month price target is $17.33, representing +491.47% upside from the current price of $2.93.
Competitors & Peers
gnlx competitorsGNLX
ACIU
ALDX
CADL
CLLS
CTNMStock Performance
Full HistoryAbout Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor ma…
what is genelux corporation · gnlx stock overview · genelux corporation company profile · who is genelux corporation ceo · gnlx NASDAQ · genelux corporation headquarters · genelux corporation business segments
About Stock Overview & Key Data
Genelux Corporation (GNLX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 26, 2023. As of the latest trading session, GNLX stock price is $2.93, with a market capitalization of $110.2M. The stock has returned +8.12% over the past 12 months and -32.80% year-to-date.
According to 3 Wall Street analysts, the consensus rating for Genelux Corporation stock is Buy, with an average 12-month price target of $17.33. In fiscal year 2025, Genelux Corporation reported revenue of $8000.00 and net income of -$32.1M. For detailed data — including Genelux Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Genelux Corporation (GNLX) stock price is $2.93. The stock is traded on NASDAQ under the ticker symbol GNLX. The 52-week range is $2.29 – $8.54.